The emergence of antibody–oligonucleotide conjugates (AOCs) addresses delivery issues with huge potential. Let's look at how to approach your development plan with molecular architecture, defining the target product profile, and CQAs.
- The Resurgence Of Fervor For Oral Delivery
- Advancing Multi-Pathology Disease-Modifying Therapy For Neurodegenerative Diseases
- Container Closure Systems For Biosimilars: Is There Regulatory Difference?
- Qualification And Validation Of Depyrogenation Tunnels And Autoclaves
- FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
- Engineering Better ADCs, Part 2: Characterization, CMC, And More
- What Patients Actually Want From Connected Drug Delivery
- Beyond Connectivity: Where Digital Technologies Create Real Value In Drug Delivery
ON-DEMAND WEBINARS
See how an amorphous solid dispersion (ASD) of acalabrutinib was designed using in vitro studies and in silico modeling. Understand how ASD formulations can enhance bioavailability.
Strengthen risk mitigation strategies while ensuring regulatory alignment. Gain valuable insights into best practices and proactive approaches for building a robust and future-ready CCS.
Explore 3D screen printing’s potential to revolutionize pharmaceutical manufacturing with scalable, customizable, multi-drug tablets and precise, patient-centric drug release profiles.
Gain valuable insights into the jet milling process and Quality by Design approach for inhalation drug delivery and their potential applications in drug development.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![iStock-1268181219-glass-vial-packaging-sterile]( "Container Closure Integrity: A Risk-Based Approach")
Container Closure Integrity: A Risk-Based ApproachContainer closure integrity is essential to protecting drug product and satisfying regulatory agencies. A risk-based approach enables creation of a robust data file for timely approval of regulatory applications.
-
![GettyImages-1311518492-vaccine-vial]( "A Glass Package Designed Specifically for Pharmaceutical Use")
A Glass Package Designed Specifically for Pharmaceutical UseA comprehensive solution for multiple glass quality issues that affect drug products is essential to avoid costly delays and drug product recalls, all while increasing patient safety.
-
![Labs 173_WestPharm_Direct 113018-143]( "Considerations In Design And Development Of Novel Combination Drug-Delivery Devices")
Considerations In Design And Development Of Novel Combination Drug-Delivery DevicesPoor scoping kills drug delivery device programs before they start. Learn how to define the right problem, assess risk early, and set boundaries that protect your timeline and budget.
-
![GettyImages-1135140461-lab-team]( "Enhancing The Solubility Of High Lipophilicity Drugs Via Spray Drying")
Enhancing The Solubility Of High Lipophilicity Drugs Via Spray DryingA new R&D project shows the solubility and dissolution characteristics of Itraconazole can be improved by helping them maintain an amorphous state after spray drying with selected hydrophilic polymers.
-
![adare osd]( "Combining Powdose® And Diffucaps® For Precise Solid Oral Dosing")
Combining Powdose® And Diffucaps® For Precise Solid Oral DosingCombining POWDOSE® and Diffucaps® enables precise, individualized solid oral dosing—improving drug delivery, patient compliance, and therapeutic outcomes in personalized medicine applications.
-
![BD Medical - Libertas Feature]( "Innovation For Subcutaneous Delivery Of Large-Volume Complex Biologics")
Innovation For Subcutaneous Delivery Of Large-Volume Complex BiologicsExplore the key findings of a new wearable injector clinical trial, including its positive impact on patient experience and the broader benefits of wearable injectors for chronic disease management.
-
![iStock-1287080337-lab-microscope-scientist-research.jpg]( "Integrated First-In-Human Services To Streamline End-To-End Development And Manufacturing")
Integrated First-In-Human Services To Streamline End-To-End Development And ManufacturingLonza’s SimpliFiH®️ Solutions offering is designed to simplify and accelerate the development pathway, even for APIs with challenging properties, such as low aqueous solubility and poor bioavailability.
-
![Doctor-patient-GettyImages-1345513639]( "Evolution Of Novel Polymers To Overcome Limits In Sustained Drug Delivery")
Evolution Of Novel Polymers To Overcome Limits In Sustained Drug DeliveryDegradable polymers evolved from aliphatic polyesters to nitrogen-bearing biomaterials such as polyurethanes and polyester amides. Explore a brief history of the development of PEA polymers.
-
![GettyImages-1371993517-syringe-vial-mask-vaccine-inject]( "Advancing Chronic Care Through GLP‑1 Innovation")
Advancing Chronic Care Through GLP‑1 InnovationGLP‑1 therapies are changing injectable care and driving rapid progress in delivery and manufacturing. See how patient needs, emerging tech, and regulations are reshaping chronic treatment.
-
![GettyImages-155373764-cryopreservation-cold-chain]( "Vials Vs. Cryobags For Cryopreservation Of Therapeutically Relevant T Cells")
Vials Vs. Cryobags For Cryopreservation Of Therapeutically Relevant T CellsExplore how COP 50 mL vials could serve as a basis for cell therapies and storage solution to help facilitate the manufacture and commercialization of cell products.
TOM'S TAKES ON DRUG DELIVERY
TALKING WITH TOM VIDEOCASTS
Fran offers keen industry and technical insights exclusively on Drug Delivery Leader.
DELIVERED BY DEGRAZIO
-
![Delivered _by _DeGrazio_Logo_Color_2]( "Container Closure Systems For Biosimilars: Is There Regulatory Difference?")
Container Closure Systems For Biosimilars: Is There Regulatory Difference?In this article, Fran DeGrazio discusses the FDA’s draft guidance on container closure systems for biosimilar products. She highlights key takeaways and offers recommendations on implications that developers of biosimilar pharmaceutical products should consider in areas such as quality, testing, and documentation.
EDITORIAL COLLECTIONS KNOWLEDGE CENTER
Our Editorial Collections examine today’s biggest scientific, operational, and patient-centered drug delivery issues. These collections help companies navigate complex development decisions with in-depth analysis, real-world examples, and guidance from industry experts.
